Phio Pharmaceuticals (PHIO) Share-based Compensation (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Share-based Compensation came in at $754000.0 in Q1 2026, up 1653.49% YoY from $43000.0 in Q1 2025, and up 567.26% on a QoQ basis from $113000.0 in Q3 2025.
Phio Pharmaceuticals (PHIO) Share-based Compensation (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Share-based Compensation data on file, last reported at $754000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 1653.49% year-over-year to $754000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $754000.0 (up 4612.5% YoY) and the FY2025 annual result came in at $30000.0, up 500.0% from the prior year.
- Share-based Compensation rose to $754000.0 in Q1 2026, from $113000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $754000.0 in Q1 2026 to a low of -$344000.0 in Q4 2022.
- A 5-year average of $70500.0 and a median of $51500.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation slumped 9500.0% — and 2026, when it jumped 1653.49%.
- Tracing PHIO's Share-based Compensation over 5 years: stood at -$344000.0 in 2022, then soared by 100.29% to $1000.0 in 2023, then tumbled by 9500.0% to -$94000.0 in 2024, then soared by 220.21% to $113000.0 in 2025, then soared by 567.26% to $754000.0 in 2026.
- The last three Share-based Compensation figures came in at $754000.0 (Q1 2026), $113000.0 (Q3 2025), and $51000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 278,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 278,000.00 |
| Jun 30, 2026 | 278,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Jun 30, 2025 | 51,000.00 |
| Jun 30, 2025 | 51,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Sep 30, 2024 | 52,000.00 |
| Sep 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 15,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |